


Case of enlarged hard tongue



- [Patient Presentation](#)
- [History](#)
- [Differential Diagnosis](#)
- [Examination](#)
- [Investigations](#)
- [Discussion](#)
- [Treatment](#)
- [Final Outcome](#)
- [References](#)
- [Evaluation - Questions & answers](#)
- [MCQ](#)

Patient Presentation

A 59 year old male presents to the medical out patient department with a one month history of progressively increasing fatigue and backache.

Acknowledgement

This case study was kindly provided by Dr Monica Mercer, MBChB from Immunopaedia

History

For the last month the patient has been feeling exhausted for no apparent reason and due to this extreme tiredness, is

finding it difficult to work and look after himself. He comes home in the late afternoon often too tired to eat and goes straight to bed; a change from his former energetic lifestyle.

He has also been complaining of some backache which he treats with over the counter analgesics and he has been suffering from more colds and flu than usual over the last year.

He has also found that for the last 6 months there has been a decline in his ability to speak clearly. His tongue has enlarged and become firm which makes moving it for speech formation and eating solid foods difficult and at times painful.

He has had an unintentional weight loss of \pm 15kg in the last 6 months.

Past medical history

Previously well, no chronic disease, no previous admissions.

Past surgical history

No history of any surgical procedures.

Family History

- Father died of a myocardial infarction at age 63 yrs with hypercholesterolaemia.
- Mother has hypertension on treatment and reports good control.
- No positive family history for any other chronic diseases including diabetes and cancer.

Social history

- Lives alone in a town house.
- Employed as an accountant.
- 30 year history of smoking.
- Significant alcohol history for 12 years, now in

recovery for the last 5 years.

Differential Diagnosis

- Anaemia
- Vitamin B12/folate deficiency
- Heart failure
- Malignancy
- Multiple myeloma
- Monoclonal gammopathy of undetermined significance (MGUS)
- Waldenstrom's macroglobulinaemia

Examination

General

- Ill looking, pale and underweight middle-aged gentleman
- Awake and alert, able to give an accurate history
- Significant dysarthria for the last 3 months, making him difficult to understand.

Vitals

- Afebrile
- Blood pressure 100/68
- Heart rate 84
- Respiratory rate 18

General

- Mild pallor
- No lymphadenopathy
- No signs of dehydration
- No jaundice
- No oedema
- No stigmata of HIV
- Tongue red and enlarged with deep imprints from the

teeth on both sides of the tongue. Very reduced mobility; unable to protrude or lift up and very limited sideways movement.

Respiratory

- Trachea centrally located.
- Chest clear on auscultation.

Cardiovascular

- No raised JVP
- Normally placed apex beat
- S1 and S2 heart sounds present, no murmurs.
- No abnormalities detected

Abdomen

- Not distended
- Soft and non tender
- Bowel sounds present
- No abnormalities detected

Neurological

- Higher function intact, although difficult to understand
- Gait normal
- Power 5/5 globally
- Tone normal globally
- Reflexes 2/4 for both upper and lower limbs
- No abnormalities detected

Dermatological/Haematological

- Some small bruises on arms and legs of various ages
- No rashes
- No petechial bleeds

Examination	Value				Normal Limits
	admission	Day 3	Day 6	Day 9	

Examination	Value				Normal Limits
WBC	5.79	6.26	6.56	6.04	(4-12 x10 ⁹ /L)
HB	5.4	12.8	10.9	13	(12.1-15.2 g/L)
Platelets	150	129	97	130	(140-450 x10 ⁹ /L)
CRP	18			14	(0-8mg/L)
Differential :					
Neutrophils		8.73			(2.00-7.5)
Monocytes		0.41			(0.18-0.80)
Lymphocytes		0.57999999999999996			(1.00-4.00)
Erythrocytes		0.03			(0.00-0.45)
Basophils		0.02			(0.00-0.20)
NA	139	140	141	146	(135-147 mmol/L)
K	6	5.3	5.4	6.2	(3.3-5.0 mmol/L)□
CL	105	108	110	119	(99-103 μmol/L)□
C02	18	16	18	11	(18-29 mmol/L)□
Urea	23	32	37	45	(2.5-6.4 mmol/L)
Creatinine	390	291	262	316	(62-115 mmol/L)
Total protein	61	69	71		(60-80g/L)
Albumin	35	31	33		(35-50g/L)
Corrected Calcium	3.09	3.1	2.96	2.8	(2.1-2.6mmol/L)
Phosphate	2.41	1.88	1.87	1.83	(1.0-1.5 mmol/L)
Magnesium	1.1599999999999999	1.01	0.97	1.02	(0.8-1.3)
IgG		3.24			(4-10)
IgM		25.7			(0.5-2.2)
IgA		<0.33			(0.5-2.2)
B-2 microglobulin		22.3			(<3.5mg/L)
HIV Elisa	negative				
Hepatitis studies, A, B and C		All negative			
Blood Culture				Negative	
Bence Jones Protein		Positive			


Examination	Value				Normal Limits
Bone Marrow Aspirate-phenotypic markers:					
CD38		Increased levels detected			
CD138		Increased levels detected			
Protein Electrophoresis		M band			

Discussion

This case study looks at a disease caused by the accumulation of neoplastic plasma B cells in bone marrow, which produce a monoclonal immunoglobulin protein found in the serum or urine. In serum, this is called an M protein or paraprotein. In urine, Bence-Jones proteins can be found which are specifically immunoglobulin light chains. We will examine the immunological basis of multiple myeloma, which is marked by upregulation of osteoclast activity due to overexpression of cytokines, causing lytic bone lesions. Multiple myeloma occurs in both men and women, but more common in men and manifests from age 40 with a peak at 60 years.

In this discussion we will look at the destructive disease process which symbolises multiple myeloma with the aid of our full colour graphics.

Multiple myeloma



Multiple myeloma is a malignancy of plasma B cells caused by alterations to genetic material following B cell activation in the germinal centres of secondary lymphoid organs. Genetic effects include primary translocations of immunoglobulin heavy/light chain genes to other chromosomes near oncogenes/cyclin genes and secondary changes including duplications of chromosomes and/or mutations in cell growth/tumour suppressor genes. Myeloma plasma B cells also express CD138 receptors for SDF-1 α , a chemokine that regulates homing to the bone marrow where bone disease develops.


Multiple myeloma is a malignancy of B cells, specifically plasma cells, which is caused by abnormal genetic changes in B cells activated in the post-germinal centre of secondary lymphoid organs. B cells express cell-surface receptors that recognise antigens displayed on

follicular dendritic cells in the germinal centres and become primed. CD4 T cell help is then required for differentiation and maturation into antibody-producing plasma cells. In individuals predisposed to multiple myeloma, DNA damage can occur following activation of B cells in the germinal centre. Specifically, abnormal DNA recombination occurs during isotype switching and affinity maturation. This results in translocation of the heavy and/or light immunoglobulin genes to other chromosomes, which influence the regulation of oncogenes or cell-proliferation genes. This primary event generates a malignant phenotype, which can be followed by secondary genetic alterations such as loss or duplication of chromosomes or genetic mutations affecting the expression of tumour-suppressor genes or oncoproteins.

Collectively, the genetic aberrations commonly found include:

1. Translocation of immunoglobulin heavy chain coding regions onto other chromosomes located near proto-oncogenes (c-myc, n-myc and MAF) or cell-proliferation proteins (cyclin D, [FGFR3](#), MMSET).
2. Duplication of chromosomes (3, 5, 7, 9 11 and 21) or loss of chromosomes (13).
3. Mutations in oncoproteins ([N-ras](#) and [K-ras](#)) or in tumour suppressor genes (p53).

DNA damage following activation of B cells in the germinal centre.




B cells are primed by B cell receptor recognition of antigens presented by follicular dendritic cells in the germinal centres of secondary lymphoid organs. CD4+ helper T cell interaction activates B cells to differentiate into plasma cells and also induces isotype switching and affinity maturation. During this process abnormal DNA recombination events translocate heavy and light immunoglobulin genes to other chromosomes and generate a malignant phenotype. Secondary genetic alterations involving substitution of chromosomes or mutations in other genes can follow. The myeloma plasma B cells continue to produce immunoglobulins resulting in a gammopathy and ultimately home to the bone marrow where bone disease develops.

Following the maturation process and isotype switching, myeloma plasma B cells produce monoclonal antibodies, although non-secretory or light chain only forms are known. This can occur with any of the immunoglobulins, IgG being the most common, IgA and IgE

occurring intermediately and IgD and IgM occurring rarely; as in this case study (IgM gammopathy).

Myeloma plasma B cells constitutively produce monoclonal immunoglobulins resulting in a gammopathy, which can cause amyloidosis due to deposition of excess insoluble proteins. Common sites for this include the tongue, kidneys and heart, as in this presenting case.

Adhesion of myeloma plasma B cells to bone marrow stromal cells.




The myeloma plasma B cells express CXCR4 receptors that bind SDF-1 α , a chemokine that regulates homing to the bone marrow. Myeloma plasma B cells also express cellular adhesion molecules, such as VLA-4, LFA-1 and MUC-1, that interact with ligands expressed on bone marrow stromal cells. Stimulation of adhesion molecules on stromal cells generates intracellular signals that promote the secretion of soluble cellular factors that help to maintain the myeloma B cells in an anti-apoptotic and drug-resistant state. Soluble cellular factors that stimulate the bone marrow stromal cells are also secreted by the myeloma B cells.

Myeloma plasma B cells migrate to the bone marrow. This homing is regulated by the chemokine stromal cell derived factor-alpha (SDF-1 α) binding to the [CXCR4](#) receptor, expressed on the myeloma plasma B cell. The myeloma plasma B cells also express cellular adhesion molecules, which interact with bone marrow stromal cell ligand. This interaction maintains myeloma B cells in an anti-apoptotic state and unresponsive to chemotherapeutic drugs.

The accompanying bone disease is characterised by the presence


of lytic bone lesions that result from an imbalance of bone formation, mediated by osteoblasts, and bone resorption, mediated by osteoclasts, which together remodel the bone microenvironment.

Bone destruction mediated by unbalanced bone formation/resorption.




Bone destruction is a hallmark of the disease primarily driven by the activation of multinucleated osteoclasts. This is mediated by stimulation of [RANK receptors](#) by [RANKL](#). In addition, the inhibitor of osteoclast activation,

[osteoprotegerin](#) (OPG), is removed and degraded by CD138 which is expressed on myeloma plasma B cells, resulting in prolonged osteoclast activation.



Furthermore, bone formation by osteoblasts is inhibited by soluble factors released by myeloma plasma B cells and the secretion of [Activin A](#) from bone marrow stromal cells.


Clinical markers of multiple myeloma



Bone destruction is exacerbated by the inhibition of osteoblast activity needed for bone formation. Myeloma plasma B cells secrete soluble factors that inhibit osteoblast activity. In addition, bone marrow stromal cells secrete osteostatin which also inhibits osteoblast function.

The process of bone resorption creates lytic bone lesions, which liberates calcium phosphates from the mineral bone matrix. This is measurable as hypercalcaemia and hyperphosphataemia in the peripheral blood, as observed in our patient. Lytic bone lesions are visible on X-rays and most often seen on chest X-rays when examining the ribs as well as the skull (where the lesions are seen as a pepper pot skull). The increased number of plasma B cells in bone marrow can be identified from a bone marrow biopsy and are usually present at greater than 10% of the total cells: indicating a neoplastic condition. To confirm the diagnosis, multiple myeloma plasma B cells can be phenotypically characterized as [CD38](#), CD138 and [CD56](#) positive and negative for [CD19](#), [CD20](#) and CD21 expression. Genetic analysis to identify abnormal translocations, loss or duplication of chromosomes or mutations can also be used to confirm the diagnosis.

Since this is a disease of post-germinal centre B cells which implies that the B cells have isotype-switched, the gammopathy usually involves IgG (most common), IgA and IgE monoclonal antibodies and rarely IgD and IgM. In this case study, a rare IgM gammopathy indicates the absence of a class switch following post-germinal activation. We can speculate that the formation of a myeloma plasma B cell phenotype was associated with incomplete heavy chain class switching or may have resulted from aberrant light chain recombination and/or affinity maturation.



To improve oxygen and nutrient supply to the myeloma plasma B cells, the formation of new blood vessels is prompted by soluble factors secreted by both bone marrow stromal cells and myeloma plasma B cells. In addition, blood vessel endothelial cells also secrete growth factors that promote the survival of the myeloma plasma B cells.

The clinical manifestation in this patient was the accumulation of large quantities of antibodies and probable deposition of insoluble complexes of light chains (amyloidosis) in organs such as the tongue, kidney and heart.

This was the likely cause of kidney and heart failure, the former indicated by high blood creatinine levels. Immunoglobulin light-chains were also detected in urine samples (Bence-Jones protein) and due to the high turnover of myeloma cells in bone marrow, elevated beta-2-microglobulin shedding occurs and this protein also accumulates to high levels in blood and reflects the staging of the cancer. As seen in our patient, excessive plasma levels of beta-2-microglobulin indicated highly advanced state of disease and poor prognosis. In addition, the large numbers of myeloma B cells probably displaced normal bone marrow haematopoietic cells and disrupted their function, as indicated by bicytopenia: reduced red cell production (anaemia) and platelet formation (thrombocytopenia). Disruption of B cell maturation in bone marrow can also impact on humoral immunity and is often related to an increased risk of infection.

List of abbreviations for soluble factors

IL-1	Interleukin 1
IL-2	Interleukin 2
IL-3	Interleukin 3
IL-4	Interleukin 4
IL-5	Interleukin 5
IL-6	Interleukin 6
IL-7	Interleukin 7
IL-8	Interleukin 8
IL-9	Interleukin 9
IL-10	Interleukin 10
IL-11	Interleukin 11
IL-12	Interleukin 12
IL-13	Interleukin 13
IL-14	Interleukin 14
IL-15	Interleukin 15
IL-16	Interleukin 16
IL-17	Interleukin 17
IL-18	Interleukin 18
IL-19	Interleukin 19
IL-20	Interleukin 20
IL-21	Interleukin 21
IL-22	Interleukin 22
IL-23	Interleukin 23
IL-24	Interleukin 24
IL-25	Interleukin 25
IL-26	Interleukin 26
IL-27	Interleukin 27
IL-28	Interleukin 28
IL-29	Interleukin 29
IL-30	Interleukin 30
IL-31	Interleukin 31
IL-32	Interleukin 32
IL-33	Interleukin 33
IL-34	Interleukin 34
IL-35	Interleukin 35
IL-36	Interleukin 36
IL-37	Interleukin 37
IL-38	Interleukin 38
IL-39	Interleukin 39
IL-40	Interleukin 40
IL-41	Interleukin 41
IL-42	Interleukin 42
IL-43	Interleukin 43
IL-44	Interleukin 44
IL-45	Interleukin 45
IL-46	Interleukin 46
IL-47	Interleukin 47
IL-48	Interleukin 48
IL-49	Interleukin 49
IL-50	Interleukin 50
IL-51	Interleukin 51
IL-52	Interleukin 52
IL-53	Interleukin 53
IL-54	Interleukin 54
IL-55	Interleukin 55
IL-56	Interleukin 56
IL-57	Interleukin 57
IL-58	Interleukin 58
IL-59	Interleukin 59
IL-60	Interleukin 60
IL-61	Interleukin 61
IL-62	Interleukin 62
IL-63	Interleukin 63
IL-64	Interleukin 64
IL-65	Interleukin 65
IL-66	Interleukin 66
IL-67	Interleukin 67
IL-68	Interleukin 68
IL-69	Interleukin 69
IL-70	Interleukin 70
IL-71	Interleukin 71
IL-72	Interleukin 72
IL-73	Interleukin 73
IL-74	Interleukin 74
IL-75	Interleukin 75
IL-76	Interleukin 76
IL-77	Interleukin 77
IL-78	Interleukin 78
IL-79	Interleukin 79
IL-80	Interleukin 80
IL-81	Interleukin 81
IL-82	Interleukin 82
IL-83	Interleukin 83
IL-84	Interleukin 84
IL-85	Interleukin 85
IL-86	Interleukin 86
IL-87	Interleukin 87
IL-88	Interleukin 88
IL-89	Interleukin 89
IL-90	Interleukin 90
IL-91	Interleukin 91
IL-92	Interleukin 92
IL-93	Interleukin 93
IL-94	Interleukin 94
IL-95	Interleukin 95
IL-96	Interleukin 96
IL-97	Interleukin 97
IL-98	Interleukin 98
IL-99	Interleukin 99
IL-100	Interleukin 100
IL-101	Interleukin 101
IL-102	Interleukin 102
IL-103	Interleukin 103
IL-104	Interleukin 104
IL-105	Interleukin 105
IL-106	Interleukin 106
IL-107	Interleukin 107
IL-108	Interleukin 108
IL-109	Interleukin 109
IL-110	Interleukin 110
IL-111	Interleukin 111
IL-112	Interleukin 112
IL-113	Interleukin 113
IL-114	Interleukin 114
IL-115	Interleukin 115
IL-116	Interleukin 116
IL-117	Interleukin 117
IL-118	Interleukin 118
IL-119	Interleukin 119
IL-120	Interleukin 120
IL-121	Interleukin 121
IL-122	Interleukin 122
IL-123	Interleukin 123
IL-124	Interleukin 124
IL-125	Interleukin 125
IL-126	Interleukin 126
IL-127	Interleukin 127
IL-128	Interleukin 128
IL-129	Interleukin 129
IL-130	Interleukin 130
IL-131	Interleukin 131
IL-132	Interleukin 132
IL-133	Interleukin 133
IL-134	Interleukin 134
IL-135	Interleukin 135
IL-136	Interleukin 136
IL-137	Interleukin 137
IL-138	Interleukin 138
IL-139	Interleukin 139
IL-140	Interleukin 140
IL-141	Interleukin 141
IL-142	Interleukin 142
IL-143	Interleukin 143
IL-144	Interleukin 144
IL-145	Interleukin 145
IL-146	Interleukin 146
IL-147	Interleukin 147
IL-148	Interleukin 148
IL-149	Interleukin 149
IL-150	Interleukin 150
IL-151	Interleukin 151
IL-152	Interleukin 152
IL-153	Interleukin 153
IL-154	Interleukin 154
IL-155	Interleukin 155
IL-156	Interleukin 156
IL-157	Interleukin 157
IL-158	Interleukin 158
IL-159	Interleukin 159
IL-160	Interleukin 160
IL-161	Interleukin 161
IL-162	Interleukin 162
IL-163	Interleukin 163
IL-164	Interleukin 164
IL-165	Interleukin 165
IL-166	Interleukin 166
IL-167	Interleukin 167
IL-168	Interleukin 168
IL-169	Interleukin 169
IL-170	Interleukin 170
IL-171	Interleukin 171
IL-172	Interleukin 172
IL-173	Interleukin 173
IL-174	Interleukin 174
IL-175	Interleukin 175
IL-176	Interleukin 176
IL-177	Interleukin 177
IL-178	Interleukin 178
IL-179	Interleukin 179
IL-180	Interleukin 180
IL-181	Interleukin 181
IL-182	Interleukin 182
IL-183	Interleukin 183
IL-184	Interleukin 184
IL-185	Interleukin 185
IL-186	Interleukin 186
IL-187	Interleukin 187
IL-188	Interleukin 188
IL-189	Interleukin 189
IL-190	Interleukin 190
IL-191	Interleukin 191
IL-192	Interleukin 192
IL-193	Interleukin 193
IL-194	Interleukin 194
IL-195	Interleukin 195
IL-196	Interleukin 196
IL-197	Interleukin 197
IL-198	Interleukin 198
IL-199	Interleukin 199
IL-200	Interleukin 200
IL-201	Interleukin 201
IL-202	Interleukin 202
IL-203	Interleukin 203
IL-204	Interleukin 204
IL-205	Interleukin 205
IL-206	Interleukin 206
IL-207	Interleukin 207
IL-208	Interleukin 208
IL-209	Interleukin 209
IL-210	Interleukin 210
IL-211	Interleukin 211
IL-212	Interleukin 212
IL-213	Interleukin 213
IL-214	Interleukin 214
IL-215	Interleukin 215
IL-216	Interleukin 216
IL-217	Interleukin 217
IL-218	Interleukin 218
IL-219	Interleukin 219
IL-220	Interleukin 220
IL-221	Interleukin 221
IL-222	Interleukin 222
IL-223	Interleukin 223
IL-224	Interleukin 224
IL-225	Interleukin 225
IL-226	Interleukin 226
IL-227	Interleukin 227
IL-228	Interleukin 228
IL-229	Interleukin 229
IL-230	Interleukin 230
IL-231	Interleukin 231
IL-232	Interleukin 232
IL-233	Interleukin 233
IL-234	Interleukin 234
IL-235	Interleukin 235
IL-236	Interleukin 236
IL-237	Interleukin 237
IL-238	Interleukin 238
IL-239	Interleukin 239
IL-240	Interleukin 240
IL-241	Interleukin 241
IL-242	Interleukin 242
IL-243	Interleukin 243
IL-244	Interleukin 244
IL-245	Interleukin 245
IL-246	Interleukin 246
IL-247	Interleukin 247
IL-248	Interleukin 248
IL-249	Interleukin 249
IL-250	Interleukin 250
IL-251	Interleukin 251
IL-252	Interleukin 252
IL-253	Interleukin 253
IL-254	Interleukin 254
IL-255	Interleukin 255
IL-256	Interleukin 256
IL-257	Interleukin 257
IL-258	Interleukin 258
IL-259	Interleukin 259
IL-260	Interleukin 260
IL-261	Interleukin 261
IL-262	Interleukin 262
IL-263	Interleukin 263
IL-264	Interleukin 264
IL-265	Interleukin 265
IL-266	Interleukin 266
IL-267	Interleukin 267
IL-268	Interleukin 268
IL-269	Interleukin 269
IL-270	Interleukin 270
IL-271	Interleukin 271
IL-272	Interleukin 272
IL-273	Interleukin 273
IL-274	Interleukin 274
IL-275	Interleukin 275
IL-276	Interleukin 276
IL-277	Interleukin 277
IL-278	Interleukin 278
IL-279	Interleukin 279
IL-280	Interleukin 280
IL-281	Interleukin 281
IL-282	Interleukin 282
IL-283	Interleukin 283
IL-284	Interleukin 284
IL-285	Interleukin 285
IL-286	Interleukin 286
IL-287	Interleukin 287
IL-288	Interleukin 288
IL-289	Interleukin 289
IL-290	Interleukin 290
IL-291	Interleukin 291
IL-292	Interleukin 292
IL-293	Interleukin 293
IL-294	Interleukin 294
IL-295	Interleukin 295
IL-296	Interleukin 296
IL-297	Interleukin 297
IL-298	Interleukin 298
IL-299	Interleukin 299
IL-300	Interleukin 300
IL-301	Interleukin 301
IL-302	Interleukin 302
IL-303	Interleukin 303
IL-304	Interleukin 304
IL-305	Interleukin 305
IL-306	Interleukin 306
IL-307	Interleukin 307
IL-308	Interleukin 308
IL-309	Interleukin 309
IL-310	Interleukin 310
IL-311	Interleukin 311
IL-312	Interleukin 312
IL-313	Interleukin 313
IL-314	Interleukin 314
IL-315	Interleukin 315
IL-316	Interleukin 316
IL-317	Interleukin 317
IL-318	Interleukin 318
IL-319	Interleukin 319
IL-320	Interleukin 320
IL-321	Interleukin 321
IL-322	Interleukin 322
IL-323	Interleukin 323
IL-324	Interleukin 324
IL-325	Interleukin 325
IL-326	Interleukin 326
IL-327	Interleukin 327
IL-328	Interleukin 328
IL-329	Interleukin 329
IL-330	Interleukin 330
IL-331	Interleukin 331
IL-332	Interleukin 332
IL-333	Interleukin 333
IL-334	Interleukin 334
IL-335	Interleukin 335
IL-336	Interleukin 336
IL-337	Interleukin 337
IL-338	Interleukin 338
IL-339	Interleukin 339
IL-340	Interleukin 340
IL-341	Interleukin 341
IL-342	Interleukin 342
IL-343	Interleukin 343
IL-344	Interleukin 344
IL-345	Interleukin 345
IL-346	Interleukin 346
IL-347	Interleukin 347
IL-348	Interleukin 348
IL-349	Interleukin 349
IL-350	Interleukin 350
IL-351	Interleukin 351
IL-352	Interleukin 352
IL-353	Interleukin 353
IL-354	Interleukin 354
IL-355	Interleukin 355
IL-356	Interleukin 356
IL-357	Interleukin 357
IL-358	Interleukin 358
IL-359	Interleukin 359
IL-360	Interleukin 360
IL-361	Interleukin 361
IL-362	Interleukin 362
IL-363	Interleukin 363
IL-364	Interleukin 364
IL-365	Interleukin 365
IL-366	Interleukin 366
IL-367	Interleukin 367
IL-368	Interleukin 368
IL-369	Interleukin 369
IL-370	Interleukin 370
IL-371	Interleukin 371
IL-372	Interleukin 372
IL-373	Interleukin 373
IL-374	Interleukin 374
IL-375	Interleukin 375
IL-376	Interleukin 376
IL-377	Interleukin 377
IL-378	Interleukin 378
IL-379	Interleukin 379
IL-380	Interleukin 380
IL-381	Interleukin 381
IL-382	Interleukin 382
IL-383	Interleukin 383
IL-384	Interleukin 384
IL-385	Interleukin 385
IL-386	Interleukin 386
IL-387	Interleukin 387
IL-388	Interleukin 388
IL-389	Interleukin 389
IL-390	Interleukin 390
IL-391	Interleukin 391
IL-392	Interleukin 392
IL-393	Interleukin 393
IL-394	Interleukin 394
IL-395	Interleukin 395
IL-396	Interleukin 396
IL-397	Interleukin 397
IL-398	Interleukin 398
IL-399	Interleukin 399
IL-400	Interleukin 400
IL-401	Interleukin 401
IL-402	Interleukin 402
IL-403	Interleukin 403
IL-404	Interleukin 404
IL-405	Interleukin 405
IL-406	Interleukin 406
IL-407	Interleukin 407
IL-408	Interleukin 408
IL-409	Interleukin 409
IL-410	Interleukin 410
IL-411	Interleukin 411
IL-412	Interleukin 412
IL-413	Interleukin 413
IL-414	Interleukin 414
IL-415	Interleukin 415
IL-416	Interleukin 416
IL-417	Interleukin 417
IL-418	Interleukin 418
IL-419	Interleukin 419
IL-420	Interleukin 420
IL-421	Interleukin 421
IL-422	Interleukin 422
IL-423	Interleukin 423
IL-424	Interleukin 424
IL-425	Interleukin 425
IL-426	Interleukin 426

progress to bone marrow involvement. For this reason MGUS alone is not predictive of the onset of multiple myeloma. Differentiating an IgM secreting multiple myeloma from Waldenstrom's macroglobulinaemia is based on the absence of bone disease in the latter. In our case, there was clear evidence of bone disease (X-ray and hypercalcaemia).

Download images for this case



[Multiple Myeloma](#)

1 file(s) 331.45 KB

[Download](#)

Treatment

- On admission patient was transfused with three units of packed red cells to correct the anaemia.
- [Zoledronic acid](#) (Zometa) was given to control the hypercalcaemia and protect the patient from other skeletal events such as spinal cord compression and pathologic fractures.
- Patient was treated with [Decadron](#) 20 mg IV daily ([dexamethasone](#))
- Patient was rehydrated and treated with IV fluids in an attempt to improve her renal function before administration of chemotherapy.
- Plan was to give patient chemotherapy- VAD ([vincristine](#), [doxorubicin](#) [Adriamycin], and dexamethasone) to decrease the tumor burden in multiple myeloma. This is typically used in preparation for autologous stem cell transplantation. VAD is administered as a 4-day continuous intravenous infusion of vincristine and doxorubicin, with 4 daily oral doses of dexamethasone.

Patients require a central venous catheter for delivery of the infusion. In selected patients, this therapy can be performed in an outpatient setting.

- Although not administered in this patient [Thalidomide](#) is a treatment of choice for multiple myeloma patients.

Download images for this case



[Multiple Myeloma](#)

1 file(s) 331.45 KB

[Download](#)

Final Outcome

The patient developed renal failure, which remained refractory to treatment. He also developed a cardiac myopathy due to cardiac amyloidosis and died two days later from cardiac failure.

Download images for this case



[Multiple Myeloma](#)

1 file(s) 331.45 KB

[Download](#)

References

Vallet S et al. (2010). "Activin A promotes multiple myeloma-induced osteolysis and is a promising target for myeloma bone disease." Proceedings of National Academy of Science USA, 1

March

[Link to Abstract](#)

Edwards CM et al. (2008). "The pathogenesis of the bone disease of multiple myeloma." Bone Jun:42(6):1007-13

[Link to Abstract](#)

Roodman GD. (2009). "Pathogenesis of myeloma bone disease." Leukemia Mar:23(3):435-411

[Link to Abstract](#)

Hideshima T et al. (2007). "Understanding multiple myeloma pathogenesis in the bone marrow to identify new therapeutic targets." Nat Rev Cancer 7(8):585-98

[Link to Abstract](#)

Download images for this case



[Multiple Myeloma](#)

1 file(s) 331.45 KB

[Download](#)

Evaluation – Questions & answers

What is the diagnosis?

Multiple myeloma, based on clinical history and findings and confirmed on IgM gammopathy, anaemia, hypercalcaemia, urine sample electrophoresis showing positive Bence-Jones protein, presence of >10% plasma B cells in bone marrow aspirate carrying CD38 and CD138 phenotypic markers, elevated Beta-2-microglobulin and lytic bone lesions seen on X-ray.

What is the cause of macroglossia in this patient?

Amyloidosis, due to deposition of excessive amounts of

insoluble immunoglobulin light chains.

What else is linked to the above condition?

Renal failure, which may develop both [acutely](#) and [chronically](#). Commonly it is caused by hypercalcaemia due to breakdown of bone but is also due to the tubular damage caused by excretion of light chains (Bence-Jones) proteins and glomerular deposition caused by [amyloid](#), [hyperuricemia](#), or local malignancy infiltrate.

Which cell-type becomes neoplastic and is implicated in multiple myeloma?

Plasma B Cells

What types of genetic aberrations occur in multiple myeloma?

- translocation of immunoglobulin heavy chain coding regions onto other chromosomes located near oncogenes or cell-proliferation proteins
- duplication or loss of chromosomes
- mutations in oncogenes or in tumour-suppressor genes.

Download images for this case



[Multiple Myeloma](#)

1 file(s) 331.45 KB

[Download](#)

Multiple Choice Questions

**Earn 1 HPCSA or 0.25 SACNASP CPD Points
– [Online Quiz](#)**

Download images for this case



[Multiple Myeloma](#)

1 file(s) 331.45 KB

[Download](#)